## VIRGINIA DEPARTMENT OF HEALTH ADAP ADVISORY COMMITTEE MEETING - 9/26/2024

NAME	ORGANIZATION	IN-PERSON	ZOOM	ABSENT
Kathleen A. McManus, MD, MSCR	UVA Health System, ID Fellow Program	$\boxtimes$		
Sarah West, MD	Infectious Disease Associates of Central Virginia			
Karen Council, OSS	Hampton Health Department			
Rebecca Dillingham, MD, MPH	Sentara Medical Center			
Saritha R. Gomadam, DO	Richmond and Henrico Health Districts			
Juan Pierce	The Minority Health Consortium	$\boxtimes$		
Mark Baker	Total Healthcare			
Stephanie Wheawill, PharmD	Virginia Department of Health/Pharmacy Services	$\boxtimes$		
Michael Bane, PharmD	CVS Pharmacies			
Laurie Forlano, DO, MPH	VDH/Office of Epidemiology			
Elaine G. Martin	VDH/Division of Disease Prevention	$\boxtimes$		
Kimberly Scott, MSPH	VDH/HIV Care Services			
Kimberly Eley, MPH, MBA	VDH/Medication Access, HIV Care Services	$\boxtimes$		
Jasmine Ford, LPN, BA	VDH/HIV Care Services	$\boxtimes$		
Briana Thomas	VDH/ Care Services			

## Meeting start time: 12:15 pm

The Committee acknowledged Dr. David Wheeler's resignation from the ADAP Advisory Committee (AAC). Dr. Wheeler is an infectious disease provider in the northern Virginia area who devoted nearly 20 years of his time and clinical expertise to serving on the AAC.

The Committee voted to update the scope of work with new language regarding the in-person requirements for state public meetings and to expand the Chair-Elect responsibilities in case the Chair is unable to fulfill duties.

The Committee voted to merge the Ryan White Part B and ADAP formularies. This change becomes effective February 1, 2025 as part of the medication access transition for uninsured clients.

The HCS Clinical Coordinator reviewed the Virginia Medication Assistance Program (VA MAP) drug utilization data.

 Bitarvy remains the most utilized single-dose antiretroviral treatment regimen for both insured and uninsured clients.

The Chair provided the committee with an overview of the REPRIEVE TRIAL, which concluded the use of daily statin drugs reduces the risk of cardiovascular disease in people living with HIV. On February 26, 2024, the Department of Health and Human Services Guidelines Panel released clinical recommendations for people with HIV who have low-to-high risk for atherosclerotic cardiovascular disease (ASCVD). VA MAP statin drug utilization data was reviewed. The Chair anticipates an increase

## VIRGINIA DEPARTMENT OF HEALTH ADAP ADVISORY COMMITTEE MEETING - 9/26/2024

in the use of statin drugs as healthcare providers become informed about the new guidelines and patients are educated about their clinical benefits.

The Medication Access Program Manager provided an overview of the medication access transition affecting uninsured clients. Effective February 1, 2025, uninsured clients will access medications at Walgreens stores across Virginia. Mail delivery will also be available. Uninsured clients will no longer access medications at local health departments or other medication pick-up sites.

The Medication Access Program Manager provided an update on the upcoming 2025 open enrollment period. The committee was reminded of the unified eligibility requirement for clients and the eligibility initiative that is closing at the end of September. As of October 1, 2024, RWHAP B services will be suspended for clients that have no current eligibility in the Provide system. Communications were shared with clients, providers and community stakeholders.

The committee chair adjourned the meeting at 1:51 p.m.